Evaluation of treatment and long-term management of anaphylaxis in pediatric departments of Greece: a 2-year nationwide survey
Main Article Content
Keywords
acute treatment, anaphylaxis, children, epinephrine, long-term management
Abstract
Background: Anaphylaxis proportions of incidence are increasing globally. However, limited data are available regarding anaphylaxis in the pediatric population of Greece.
Purpose: The aim of the study was to evaluate management of anaphylaxis in Greek pediatric departments.
Methods: We performed a questionnaire-based study of children aged less than 16 years presenting with anaphylaxis in 10 national pediatric hospitals over a period of 2 years. Management of anaphylaxis was assessed prior to and after an informative intervention.
Results: In all, 127 cases of anaphylaxis were identified. Epinephrine was administered in almost half of all cases (51.2%), predominantly through intramuscular route (88.5%), while the majority of anaphylaxis patients were treated with antihistamines (92.9%) and corticosteroids (70.1%). Epinephrine was more likely administered by physicians if the elicitor was a drug (P < 0.003). Regarding long-term management, an epinephrine auto-injector was prescribed in 66.9% of patients. Follow-up information was available for most of the patients (92.9%), the majority of whom (76.3%) were referred to an allergist. More than half of these patients (63.6%) had a documented allergy follow-up, which identified a causative allergen in 53.3% of cases. No statistically significant differences were recorded prior to and after the intervention regarding management of anaphylaxis.
Conclusions: This nationwide study highlighted the necessity of further improvement in terms of anaphylaxis treatment and secondary prevention measures. This presupposes appropriate education and training of healthcare professionals, thus contributing to proper and comprehensive care of the pediatric population.
References
2. Fischer D, Vander Leek TK., Ellis, AK, Kim H. Anaphylaxis. Allergy Asthma Clin Immunol. 2018 Sep 12;14(Suppl 2):54. 10.1186/s13223-018-0283-4
3. Cardona V, Ansotegui IJ, Ebisawa M, El-Gamal Y, Fernandez Rivas M, Fineman S, et al. World Allergy Organization Anaphylaxis Guidance 2020. World Allergy Organ J. 2020 Oct 30;13(10):100472. 10.1016/j.waojou.2020.100472
4. Wang Y, Allen KJ, Suaini NHA, McWilliam V, Peters RL, Koplin JJ. The global incidence and prevalence of anaphylaxis in children in the general population: A systematic review. Allergy. 2019 Jun;74(6):1063–80. 10.1111/all.13732
5. Motosue MS, Bellolio MF, Van Houten HK, Shah ND, Campbell RL. National trends in emergency department visits and hospitalizations for food-induced anaphylaxis in US children. Pediatr Allergy Immunol. 2018 Aug;29(5):538–44. 10.1111/pai.12908
6. Conrado AB, Ierodiakonou D, Gowland MH, Boyle RB, Turner PJ. Food anaphylaxis in the United Kingdom: Analysis of national data, 1998–2018. Br Med J (BMJ). 2021 Feb 17;372:n251. 10.1136/bmj.n251
7. Nocerino R, Leone L, Cosenza L, Berni Canani R. Increasing rate of hospitalizations for food-induced anaphylaxis in Italian children: An analysis of the Italian Ministry of Health database. J Allergy Clin Immunol. 2015 Mar;135(3):833–5.e3. 10.1016/j.jaci.2014.12.1912
8. Pyrpyris N, Kritikou M, Aggelidis X, Manolaraki I, Makris M, Papadopoulos NG, Xepapadaki P. Anaphylaxis in children and adolescents: Greek data analysis from the European Anaphylaxis Registry (NORA). J Pers Med. 2022 Sep 30;12(10):1614. 10.3390/jpm12101614
9. Mullins RJ, Dear KB, Tang ML. Time trends in Australian hospital anaphylaxis admissions in 1998–1999 to 2011–2012. J Allergy Clin Immunol. 2015 Aug;136(2):367–75. 10.1016/j.jaci.2015.05.009
10. Tejedor Alonso MA, Moro Moro M, Múgica García MV. Epidemiology of anaphylaxis. Clin Exp Allergy. 2015 Jun;45(6):1027–39. 10.1111/cea.12418
11. Michelson KA, Monuteaux MC, Neuman MI. Variation and trends in anaphylaxis care in United States children’s hospitals. Acad Emerg Med. 2016 May;23(5):623–7. 10.1111/acem.12922
12. Quoc QL, Bich TCT, Jang JH, Park HS. Recent update on the management of anaphylaxis. Clin Exp Emerg Med. 2021 Sep;8(3):160–72. 10.15441/ceem.21.121
13. Sclar DA, Lieberman PL. Anaphylaxis: Underdiagnosed, underreported, and undertreated. Am J Med. 2014 Jan;127(1 Suppl):S1–5. 10.1016/j.amjmed.2013.09.007
14. Dribin TE, Motosue MS, Campbell RL. Overview of allergy and anaphylaxis. Emerg Med Clin North Am. 2022 Feb;40(1):1–17. 10.1016/j.emc.2021.08.007
15. Shroba JA. Infant anaphylaxis: Diagnostic and treatment challenges. J Am Assoc Nurse Pract. 2020 Feb;32(2):176–83. 10.1097/JXX.0000000000000386
16. Australasian Society of Clinical Immunology and Allergy (ASCIA). Guidelines for the acute management of anaphylaxis. Accessed 19 April 2021.
17. Kim H, Fischer D. Anaphylaxis. All Asth Clin Immun. 2011;7(Suppl 1):S6. 10.1186/1710-1492-7-S1-S6
18. Fleming JT, Clark S, Camargo CA Jr, Rudders SA. Early treatment of food induced anaphylaxis with epinephrine is associated with a lower risk of hospitalization. J Allergy Clin Immunol Pract. 2015 Jan–Feb;3(1):57–62. 10.1016/j.jaip.2014.07.004
19. Alqurashi W, Stiell I, Chan K, Neto G, Alsadoon A, Wells G. Epidemiology and clinical predictors of biphasic reactions in children with anaphylaxis. Ann Allergy Asthma Immunol. 2015 Sep;115(3):217–23.e2. 10.1016/j.anai.2015.05.013
20. Ellis AK. Priority role of epinephrine in anaphylaxis further underscored—The impact on biphasic anaphylaxis. Ann Allergy Asthma Immunol. 2015 Sep;115(3):165. 10.1016/j.anai.2015.06.024
21. Simons FE. Anaphylaxis. J Allergy Clin Immunol. 2010 Feb;125 (Suppl 2):S161–81. 10.1016/j.jaci.2009.12.981
22. Simons FE. Anaphylaxis, killer allergy: Long-term management in the community. J Allergy Clin Immunol. 2006 Feb;117(2):367–77. 10.1016/j.jaci.2005.12.002
23. Fineman SM, Bowman SH, Campbell RL, Dowling P, O’Rourke D, Russell WC, et al. Addressing barriers to emergency anaphylaxis care: From emergency medical services to emergency department to outpatient follow-up. Ann Allergy Asthma Immunol. 2015 Oct;115(4):301–5. 10.1016/j.anai.2015.07.008
24. Russell WS, Farrar JR, Nowak R, Hays DP, Scmitz N, Wood J, et al. Evaluating the management of anaphylaxis in US emergency departments: Guidelines vs. practice. World J Emerg Med. 2013;4(2):98–106. 10.5847/wjem.j.issn.1920-8642.2013.02.003
25. Robinson M, Greenhawt M, Stukus DR. Factors associated with epinephrine administration for anaphylaxis in children before arrival to the emergency department. Ann Allergy Asthma Immunol. 2017 Aug;119(2):164–9. 10.1016/j.anai.2017.06.001
26. Sidhu N, Jones S, Perry T, Thompson T, Storm E, Melguizo Castro AS, et al. Evaluation of anaphylaxis management in a pediatric emergency department. Pediatr Emerg Care. 2016 Aug;32(8):508–13. 10.1097/PEC.0000000000000864
27. Simons FE, Ardusso LR, Bilo MB, El-Gamal YM, Ledford DK, Ring J, et al. World Allergy Organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J. 2011 Feb;4(2):13–37. 10.1097/WOX.0b013e318211496c
28. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet.1977 Feb 26;1(8009):466–9. 10.1016/S0140-6736(77)91953-5
29. Grabenhenrich LB, Dölle S, Ruëff F, Renaudin JM, Scherer K, Pföhler C, et al. Epinephrine in severe allergic reactions: The European anaphylaxis register. J Allergy Clin Immunol Pract. 2018 Nov–Dec;6(6):1898–906.e1. 10.1016/j.jaip.2018.02.026
30. Gaspar Â, Santos N, Faria E, Pereira AM, Gomes E, Câmara R, et al. Anaphylaxis in children and adolescents: The Portuguese Anaphylaxis Registry. Pediatr Allergy Immunol. 2021 Aug;32(6):1278–86. 10.1111/pai.13511
31. Rangkakulnuwat P, Sutham K, Lao-Araya M. Anaphylaxis: Ten-year retrospective study from a tertiary-care hospital in Asia. Asian Pac J Allergy Immunol. 2020 Mar;38(1):31–9.
32. Pouessel G, Antoine M, Pierache A, Dubos F, Lejeune S, Deschildre A. Pediatric Emergency Medicine Group. Factors associated with the underuse of adrenaline in children with anaphylaxis. Clin Exp Allergy. 2021 May 51(5):726–9. 10.1111/cea.13821
33. Prince BT, Mikhail I, Stukus DR. Underuse of epinephrine for the treatment of anaphylaxis: Missed opportunities. J Asthma Allergy. 2018 Jun 20;11:143–51. 10.2147/JAA.S159400
34. Anagnostou K, Turner PJ. Myths, facts and controversies in the diagnosis and management of anaphylaxis. Arch Dis Child. 2019 Jan;104(1):83–90. 10.1136/archdischild-2018-314867
35. Simon FE, Clark S, Camargo CA Jr. Anaphylaxis in the community: Learning from the survivors. J Allergy Clin Immunol. 2009 Aug;124(2):301–6. 10.1016/j.jaci.2009.03.050
36. Arroabarren E, Lasa EM, Olaciregui I, Sarasqueta C, Muñoz JA, Pérez-Yarza EG. Improving anaphylaxis management in a pediatric emergency department. Pediatr Allergy Immunol. 2011 Nov;22(7):708–14. 10.1111/j.1399-3038.2011.01181.x
37. Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: Intramuscular versus subcutaneous injection. J Allergy Clin Immunol. 2001 Nov;108(5):871–3. 10.1067/mai.2001.119409
38. Campbell RL, Bellolio MF, Knutson BD, Bellamkonda VR, Fedko MG, Nestler DM, et al. Epinephrine in anaphylaxis: Higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrine. J Allergy Clin Immunol. 2015 Jan–Feb;3(1):76–80. 10.1016/j.jaip.2014.06.007
39. Simons FE, Roberts JR, Gu X, Simons KJ. Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol.1998 Jan;101(Pt 1):33–7. 10.1016/S0091-6749(98)70190-3
40. Vera MJ, Tagaro IC. Anaphylaxis diagnosis and management in the emergency department of a tertiary hospital in the Philippines. Asia Pac Allergy. 2020 Jan 13;10(1):e1. 10.5415/apallergy.2020.10.e1
41. Jeong K, Ye YM, Kim SH, Kim KW, Kim JH, Kwon JW, et al. A multicenter anaphylaxis registry in Korea: Clinical characteristics and acute treatment details from infants to older adults. World Allergy Organ J. 2020 Aug 11;13(8):100449. 10.1016/j.waojou.2020.100449
42. Francuzik W, Dölle-Bierke S, Knop M, Scherer Hofmeier K, Cichocka-Jarosz E, García BE, et al. Refractory anaphylaxis: Data from the European anaphylaxis registry. Front Immunol. 2019 Oct 18;10:2482. 10.3389/fimmu.2019.02482
43. Pouessel G, Deschildre A, Dribin TE, Ansotegui IJ, Cardona V, Chinthrajah RS, et al. Refractory anaphylaxis: A new entity for severe anaphylaxis. J Allergy Clin Immunol Pract. 2023 Jul;11(7):2043–8. 10.1016/j.jaip.2023.04.037
44. Pouessel G, Tanno LK, Claverie C, Lejeune S, Labreuche J, Dorkenoo A, et al. Fatal anaphylaxis in children in France: Analysis of national data. Pediatr Allergy Immunol. 2018 Feb;29(1):101–4. 10.1111/pai.12828
45. Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the United States, 1999–2010: Temporal patterns and demographic associations. J Allergy Clin Immunol. 2014 Dec;134(6):1318–28.e7. 10.1016/j.jaci.2014.08.018
46. Cardinale F, Amato D, Mastrototaro MF, Caffarelli C, Crisafulli G, Franceschini F, et al. Drug-induced anaphylaxis in children. Acta Biomed. 2019 Jan 30;90(3-S):30–5.
47. Ezzat MHM, Shousha GAH, Gabal HAMS, Mousa MM. Anaphylaxis in children: Experience of an Egyptian center. Int J Allergy Asthma (IJAA). 2021;107. 10.29011/IJAA-107.100007
48. Jiang N, Xu W, Xiang L. Age-related differences in characteristics of anaphylaxis in Chinese children from infancy to adolescence. World Allergy Organ J. 2021 Nov 18;14(11):100605. 10.1016/j.waojou.2021.100605
49. Shaker MS, Wallace DV, Golden DBK, Oppenheimer J, Bernstein JA, Campbell RL, et al. Anaphylaxis—A 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020 Apr;145(4):1082–123. 10.1016/j.jaci.2020.01.017
50. Muraro A, Worm M, Alviani C, Cardona V, Dunn Galvin A, Garvey LH, et al. European Academy of Allergy, Clinical Immunology Food Allergy, Anaphylaxis Guidelines Group. EAACI guideline: Anaphylaxis (2021 update). Allergy. 2022 Feb 77(2):357–77. 10.1111/all.15032
51. Nurmatov UB, Rhatigan E, Simons FER, Sheikh A. H2 antihistamines for the treatment of anaphylaxis with and without shock: A systematic review. Ann Allergy Asthma Immunol. 2014 Feb;112(2):126–31. 10.1016/j.anai.2013.11.010
52. Auth RD, Zheng T, Berk J. Things We Do for No Reason™: Routine use of corticosteroids for the treatment of anaphylaxis. J Hosp Med. 2022 Mar;17(3):211–4. 10.12788/jhm.3665
53. Alqurashi W, Ellis AK. Do corticosteroids prevent biphasic anaphylaxis? J Allergy Clin Immunol Pract. 2017 Sep–Oct;5(5):1194–205. 10.1016/j.jaip.2017.05.022
54. Campbell DE. Australia. Anaphylaxis management: Time to re-evaluate the role of corticosteroids. J Allergy Clin Immunol Pract. 2019 Sep–Oct;7(7):2239–40. 10.1016/j.jaip.2019.07.005
55. Turner PJ, Jerschow E, Umasunthar T, Lin R, Campbell DE, Boyle RJ. Fatal anaphylaxis: Mortality rate and risk factors. J Allergy Clin Immunol Pract. 2017 Sep–Oct;5(5):1169–78. 10.1016/j.jaip.2017.06.031
56. Gabrielli S, Clarke A, Morris J, Eisman H, Gravel J, Enarson P, et al. Evaluation of pre-hospital management in a Canadian emergency department anaphylaxis cohort. J Allergy Clin Immunol Pract. 2019 Sep–Oct;7(7):2232–8.e3.10.1016/j.jaip.2019.04.018
57. Alvarez-Perea A, Ameiro B, Morales C, Zambrano G, Rodríguez A, Guzmán M, et al. Anaphylaxis in the pediatric emergency department: Analysis of 133 cases After an allergy workup. J Allergy Clin Immunol Pract. 2017 Sep–Oct;5(5):1256–63.10.1016/j.jaip.2017.02.011
58. Tritt A, Gabrielli S, Zahabi S, Clarke A, Moisan J, Eisman H, et al. Long-term management of cases of venom-induced anaphylaxis is suboptimal. Ann Allergy Asthma Immunol. 2018 Aug;121(2):229–34.e1 10.1016/j.anai.2018.04.006
59. Burnell FJ, Keijzers G, Smith P. Review article: Quality of follow-up care for anaphylaxis in the emergency department. Emerg Med Australas. 2015 Oct;27(5):387–93. 10.1111/1742-6723.12458
60. Muraro A, Worm M, Alviani C, Cardona V, DunnGalvin A, Garvey LH, et al. European Academy of Allergy and Clinical Immunology, Food Allergy, Anaphylaxis Guidelines Group. EAACI guidelines: Anaphylaxis (2021 update). Allergy. 2022 Feb 77(2):357–77. 10.1111/all.15032
61. Ahmead M, Daghlas F. The effect of the COVID-19 pandemic on the provision of outpatient clinic services in East Jerusalem hospitals: Patients’ perspectives. Front Public Health. 2023 Nov 24;11:1252449. 10.3389/fpubh.2023.1252449
62. Singh K, Xin Y, Xiao Y, Quan J, Kim D, Nguyen TPL, et al. Impact of the COVID-19 pandemic on chronic disease care in India, China, Hong Kong, Korea, and Vietnam. Asia Pacific J Public Health. 2022;34:392–400. 10.1177/10105395211073052
63. Noncommunicable Diseases, Rehabilitation and Disability (NCD). The impact of the COVID-19 pandemic on noncommunicable disease resources and services: Results of a rapid assessment. Geneva, Switzerland: World Health Organization (WHO); 2020. Available from: https://apps.who.int/iris/handle/10665/334136 (Accessed: December 29, 2021).
64. Arsenault C, Gage A, Kim MK, Kapoor NR, Akweongo P, Amponsah F, et al. COVID-19 and resilience of healthcare-systems in ten countries. Nat Med. 2022;28:1314–24. 10.1038/s41591-022-01750-1
65. Campbell RL Park MA, Kueber Jr MA, Lee S, Hagan JB. Outcomes of allergy/immunology follow-up after an emergency department evaluation for anaphylaxis. J Allergy Clin Immunol Pract. 2015 Jan–Feb;3(1):88–93. 10.1016/j.jaip.2014.07.011
66. Landsman-Blumberg PB, Wei W, Douglas D, Smith DM, Clark S, Camargo Jr CA. Food-induced anaphylaxis among commercially insured US adults: Patient concordance with post-discharge care guidelines. J Allergy Clin Immunol Pract. 2013 Nov–Dec;1(6):595–601.e1. 10.1016/j.jaip.2013.07.003.